Phase II
Data shared in oral presentation at ESMO Congress 2019 show telaglenastat doubles median progression-free survival (PFS) in heavily pre-treated patients with advanced disease, reduced risk of death by 36% (HR=0.64, p=0.079 one-sided)
Immutep Limited announces that the requisite number of predefined patient responses has been exceeded in cohort 1 of Part A) of the TACTI-002 Phase II clinical trial based on an interim analysis.
Adrenomed AG, the vascular integrity company, announced the successful completion of patient enrollment in the proof-of-concept Phase II trial, AdrenOSS-2, evaluating Adrecizumab in patients with early septic shock.
NorthSea Therapeutics B.V. announces dosing of the first patient with icosabutate in a phase 2b dose ranging study.
Summit Therapeutics plc and collaborators will present new data analyses from the Phase 2 clinical trial of ridinilazole in patients with C. difficile infection (‘CDI’) at ID Week 2019, taking place 2-6 October 2019 in Washington, DC.
Teijin Pharma Limited announced that new topline results from a Phase II clinical trials, showing that TMX-049, which is being developed for the treatment of diabetic kidney disease in type 2 diabetes, achieved its primary endpoint for efficacy.
Ovid Therapeutics Inc. announced positive initial data from the ENDYMION trial, a Phase 2 open-label extension study of soticlestat in patients with rare developmental and epileptic encephalopathies.
Immutep Limited announces that it will receive a milestone payment from GSK of GBP 4 million related to the the first patient being dosed in GSK’s Phase II clinical trial evaluating GSK2831781 in ulcerative colitis.
Immutep Limited announces that it will receive a milestone payment from GSK of £4 million related to the first patient being dosed in GSK’s Phase II clinical trial evaluating GSK2831781 in ulcerative colitis.
It was a moderately busy week for clinical trial news. Here’s a look.
PRESS RELEASES